MAIA Biotechnology, Inc.MAIA
Price (close)
$1.25
Market cap
$76.0M
P/E
—
Revenue (TTM)
—
Net income
-$26.8M
Dividend yield
—
1-year total return
-20.4%
Net margin
—
Revenue growth
—
Debt / equity
—
What MAIA Biotechnology, Inc. does.
MAIA Biotechnology, Inc. (MAIA, the Company, we, or us) is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Ateganosine (THIO, 6-thio-dG or 6-thio-2
‘-deoxyguanosine), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting
and immunogenicity. In July 2022, the first patient was administered with ateganosine in our Phase 2 human trial (THIO-101) in Australia.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | — |
| Net income | — | -$12.5M | -$15.8M | -$19.8M | -$23.3M | -$22.4M |
More on MAIA.
- MAIA Biotechnology, Inc. summary
- MAIA Biotechnology, Inc. financial statements
- MAIA Biotechnology, Inc. key metrics
- MAIA Biotechnology, Inc. health scores and style box
- MAIA Biotechnology, Inc. earnings
- MAIA Biotechnology, Inc. dividends
- MAIA Biotechnology, Inc. valuation
- MAIA Biotechnology, Inc. ownership and insiders
- MAIA Biotechnology, Inc. peers
Figures from MAIA Biotechnology, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.